Ranger Investment Management L.P. Purchases New Shares in LeMaitre Vascular, Inc. $LMAT

Key Points

• Ranger Investment Management bought 219,307 shares of LeMaitre Vascular valued at approximately $21.0 million, representing about 0.96% of the company. Institutional investors collectively own 84.64% of LMAT.
• LeMaitre Vascular reported quarterly earnings of $0.74 per share, below the $0.81 consensus estimate, while revenue rose 9.6% year over year to $70.38 million.
• The company declared a quarterly dividend of $0.25 per share, equivalent to a $1.00 annualized payout and a 1.2% yield. Analysts maintain a consensus “Hold” rating with an average price target of $110.60.

Ranger Investment Management L.P. purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 219,307 shares of the medical instruments supplier's stock, valued at approximately $21,045,000. Ranger Investment Management L.P. owned approximately 0.96% of LeMaitre Vascular at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. purchased a new position in shares of LeMaitre Vascular in the second quarter worth approximately $102,000. Quantbot Technologies LP purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $1,353,000. Emerald Investment Advisers LLC purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $3,490,000. Summit Creek Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $4,719,000. Finally, BlackRock Inc. acquired a new position in LeMaitre Vascular in the 2nd quarter worth approximately $314,075,000. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $81.86 on Monday. The company's 50 day moving average price is $94.38 and its 200 day moving average price is $99.67. LeMaitre Vascular, Inc. has a 52 week low of $78.65 and a 52 week high of $118.01. The company has a market capitalization of $1.87 billion, a PE ratio of 28.72, a PEG ratio of 2.36 and a beta of 0.53. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The firm's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 EPS. Research analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be issued a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. LeMaitre Vascular's dividend payout ratio (DPR) is currently 35.09%.

Wall Street Analyst Weigh In

Several analysts have issued reports on LMAT shares. Citizens Jmp boosted their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a "market outperform" rating in a research note on Wednesday, May 6th. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Citigroup reaffirmed a "market outperform" rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Zacks Research downgraded LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. Finally, Weiss Ratings lowered LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, August 14th. Three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $110.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source